Clinical Trials Browser

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms

Triple Negative Breast Neoplasms

Anatomic Stage III Breast Cancer AJCC v8

Breast Cancer Metastatic

Breast Neoplasms, Inflammatory Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Carcinoma In Situ, Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Male

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Breast Neoplasms

Glioblastoma

Breast Neoplasms

Breast Neoplasms, Carcinoma, Lobular

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Risk Reduction Behavior

Breast Neoplasms

Carcinoma, Intraductal, Noninfiltrating

ER+ Breast Cancer

Breast Neoplasms

Neuroendocrine Tumors

Premenopausal Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Ovarian Neoplasms

Anatomic Stage IV Breast Cancer AJCC v8

Breast Neoplasms

Erectile Dysfunction, Prostatic Neoplasms, Lower Urinary Tract Symptoms

Ovarian Neoplasms

Clinical Trials

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

preEMBER

OMAHA-015

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

AMEERA-3

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Next MONARCH 1

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

ETHAN - ET for Male BC

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

LDTam

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

BabyTears

ADEPT

TOLERANT

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

METALLICA

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

CAMERAN

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

PHERGain

KARISMA2

ASPIRE

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

TRAK-ER

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

HORMONET

MORE-T

TP-II

WinPro

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

REGOVAR

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy